The rapid pace of Chinese clinical trials and deal-making is forcing European biotechs to reconsider their traditional US-centric partnering strategy. China is now viewed as a legitimate, alternative partner for development and funding, a perspective that US players may be underappreciating.
The industry is on the cusp of a seismic therapeutic shift. Major Phase 3 readouts for siRNA/ASO in common diseases are expected in the next year. Simultaneously, in vivo CAR-T for autoimmunity represents a move from treating symptoms to potentially curing diseases, a true revolutionary step.
Data from BioCentury and McKinsey highlights Spain's rapid emergence as a key global center for clinical trials, especially in oncology. This trend signals a significant shift in the European R&D landscape, making Spain a critical location for biopharma companies to execute their clinical strategies.
While European biotechs have historically prided themselves on capital efficiency, this mindset is now seen as a potential flaw in a global race for innovation. The focus is shifting towards bolder financing to generate value-driving data quickly, as efficiency is meaningless if a competitor reaches the market first.
Dr. Richard Pazder, former head of the FDA's Oncology Center of Excellence, cautions that recent agency announcements often lack internal planning and are disconnected from operational reality. Staff frequently learn about new policies from press releases, leading to chaotic implementation and inconsistency.
Dr. Richard Pazder warns that the FDA's new real-time review program could allow reviewers with no clinical trial experience to scrutinize ongoing trial data. This creates a risk of premature, misguided interventions based on small patient numbers, potentially jeopardizing promising therapies.
Despite discussions of European self-reliance, its capital markets remain inadequate for scaling biotech companies. Over the past 10 years, only three biotechs managed to raise over €100 million in an IPO on a European exchange, compared to 27 European biotechs that achieved this on NASDAQ in the same period.
To achieve a 4% growth rate by 2031, large pharma firms need to acquire $69 billion in new sales. However, an analysis shows only 28 suitable public targets existed recently, and 10 have already been acquired in the last two years, creating a stark supply-demand imbalance for late-stage assets.
The M&A landscape is no longer dominated solely by big pharma. Mid-sized pharmas and large biotechs are emerging as aggressive acquirers. One global head of BD at a mid-sized firm noted they won a recent billion-dollar deal by moving from data room to offer in just three weeks, signaling a new competitive speed.